Expression, mutational analysis and in vitro response of imatinib mesylate and nilotinib target genes in ovarian granulosa cell tumors

被引:26
作者
Chu, Simon [1 ]
Alexiadis, Maria [1 ]
Fuller, Peter J. [1 ]
机构
[1] Prince Henrys Inst Med Res, Clayton, Vic 3168, Australia
基金
英国医学研究理事会;
关键词
tyrosine kinase; c-kit; c-Abl; platelet-derived growth factor receptors; ovarian cancer;
D O I
10.1016/j.ygyno.2007.09.017
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objectives. Granulosa cell tumors of the ovary (GCT) represent similar to 5% of malignant ovarian tumors. Surgery remains the primary modality of therapy and treatment options for advanced disease are limited. The molecular pathogenesis of GCT is not known but is likely to involve activation of tyrosine kinase-mediated cell signaling pathways. A recent case report of a patient with advanced recurrent GCT responding to the tyrosine kinase inhibitor, imatinib mesylate prompted us to explore a role for these therapies in GCT. Methods. The expression of the imatinib-sensitive tyrosine kinases, c-kit, c-Abl, PDGFR-alpha and PDGFR-beta, was determined using RT-PCR in a panel of GCT. Activating mutations of c-kit and PDGFR-alpha were also sought. The functional response was examined in two human-derived GCT cell lines. Results. All four kinases were expressed but at levels lower than those observed in pre-menopausal ovarian samples. Mutations in c-kit and PDGFR-alpha were not found. Both cell lines responded to imatinib and to the second generation, tyrosine kinase inhibitor, nilotinib, with dose-dependent decreases in cell proliferation and viability. These responses paralleled the imatinib-sensitive, K562 cell line but at similar to 240- and similar to 1000-fold higher concentrations of imatinib and nilotinib, respectively. Conclusions. Our study suggests that human GCT, in general, are unlikely to respond to imatinib or nilotinib therapy. The response of the cell lines at high concentrations implies an "off-target" effect, which suggests that a tyrosine kinase inhibitor, of appropriate specificity, may represent a therapeutic option in GCT. (c) 2007 Elsevier Inc. All rights reserved.
引用
收藏
页码:182 / 190
页数:9
相关论文
共 36 条
  • [1] ALEXIADIS M, 2006, INT J GYNECOL CANCER, V16, P1
  • [2] Sunitinib maleate
    Atkins, M
    Jones, CA
    Kirkpatrick, P
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2006, 5 (04) : 279 - 280
  • [3] Imatinib mesylate inhibits Leydig cell tumor growth:: Evidence for in vitro and in vivo activity
    Basciani, S
    Brama, M
    Mariani, S
    De Luca, G
    Arizzi, M
    Vesci, L
    Pisano, C
    Dolci, S
    Spera, G
    Gnessi, L
    [J]. CANCER RESEARCH, 2005, 65 (05) : 1897 - 1903
  • [4] Treating cancer's kinase 'addiction'
    Baselga, J
    Arribas, J
    [J]. NATURE MEDICINE, 2004, 10 (08) : 786 - 787
  • [5] Glivec (ST1571, Imatinib), a rationally developed, targeted anticancer drug
    Capdeville, R
    Buchdunger, E
    Zimmermann, J
    Matter, A
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2002, 1 (07) : 493 - 502
  • [6] A mutation-created novel intra-exonic pre-mRNA splice site causes constitutive activation of KIT in human gastrointestinal stromal tumors
    Chen, LL
    Sabripour, M
    Wu, EF
    Prieto, VG
    Fuller, G
    Frazier, ML
    [J]. ONCOGENE, 2005, 24 (26) : 4271 - 4280
  • [7] Transrepression of estrogen receptor β signaling by nuclear factor-κB in ovarian granulosa cells
    Chu, S
    Nishi, Y
    Yanase, T
    Nawata, H
    Fuller, PJ
    [J]. MOLECULAR ENDOCRINOLOGY, 2004, 18 (08) : 1919 - 1928
  • [8] FSH-regulated gene expression profiles in ovarian tumours and normal ovaries
    Chu, S
    Rushdi, S
    Zumpe, ET
    Mamers, P
    Healy, DL
    Jobling, T
    Burger, HG
    Fuller, PJ
    [J]. MOLECULAR HUMAN REPRODUCTION, 2002, 8 (05) : 426 - 433
  • [9] Estrogen receptor isoform gene expression in ovarian stromal and epithelial tumors
    Chu, S
    Mamers, P
    Burger, HG
    Fuller, PJ
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2000, 85 (03) : 1200 - 1205
  • [10] CROSIER PS, 1993, BLOOD, V82, P1151